Bacillus Calmette-Guérin vaccination reduces the severity and progression of tuberculosis in badgers.
about
BCG vaccination reduces risk of tuberculosis infection in vaccinated badgers and unvaccinated badger cubsThe Wild Side of Disease Control at the Wildlife-Livestock-Human Interface: A ReviewProtection against tuberculosis in Eurasian wild boar vaccinated with heat-inactivated Mycobacterium bovisBadger responses to small-scale culling may compromise targeted control of bovine tuberculosis.Assessment of BCG and inactivated Mycobacterium bovis vaccines in an experimental tuberculosis infection model in sheep.Comparing badger (Meles meles) management strategies for reducing tuberculosis incidence in cattle.The contribution of badgers to confirmed tuberculosis in cattle in high-incidence areas in England.Mycobacterium bovis: A Model Pathogen at the Interface of Livestock, Wildlife, and HumansDuration of immunity against Mycobacterium bovis following neonatal vaccination with bacillus Calmette-Guérin Danish: significant protection against infection at 12, but not 24, months.Field Trial of an Aerially-Distributed Tuberculosis Vaccine in a Low-Density Wildlife Population of Brushtail Possums (Trichosurus vulpecula)Model of Selective and Non-Selective Management of Badgers (Meles meles) to Control Bovine Tuberculosis in Badgers and Cattle.Oral Vaccination of Free-Living Badgers (Meles meles) with Bacille Calmette Guérin (BCG) Vaccine Confers Protection against TuberculosisPostexposure subunit vaccination against chronic enteric mycobacterial infection in a natural host.Progress in Oral Vaccination against Tuberculosis in Its Main Wildlife Reservoir in Iberia, the Eurasian Wild Boar.Deciphering serology to understand the ecology of infectious diseases in wildlife.Control strategies for wildlife tuberculosis in Ireland.Overview of vaccination trials for control of tuberculosis in cattle, wildlife and humans.Field evaluation of the efficacy of Mycobacterium bovis BCG vaccine against tuberculosis in goats.Badger macrophages fail to produce nitric oxide, a key anti-mycobacterial effector molecule.Assessment of an oral Mycobacterium bovis BCG vaccine and an inactivated M. bovis preparation for wild boar in terms of adverse reactions, vaccine strain survival, and uptake by nontarget species.Heterogeneity in the risk of Mycobacterium bovis infection in European badger (Meles meles) cubs.A New Experimental Infection Model in Ferrets Based on Aerosolised Mycobacterium bovis.Mycobacterium tuberculosis Complex Members Adapted to Wild and Domestic Animals.Association of quantitative interferon-γ responses with the progression of naturally acquired Mycobacterium bovis infection in wild European badgers (Meles meles).Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): bovine tuberculosisPathogenesis of Mycobacterium bovis Infection: the Badger Model As a Paradigm for Understanding Tuberculosis in Animals.Modelling the impact of vaccination on tuberculosis in badgers.Blood thicker than water: kinship, disease prevalence and group size drive divergent patterns of infection risk in a social mammal.Exposure of nontarget wildlife to candidate TB vaccine baits deployed for European badgersExpert opinion-based relative landscape isolation maps for badgers across England and WalesThe status of tuberculosis in European wild mammalsEfficacy and Safety of BCG Vaccine for Control of Tuberculosis in Domestic Livestock and WildlifeModeling as a Decision Support Tool for Bovine TB Control Programs in Wildlife
P2860
Q27335059-170462A5-6821-4C93-BA81-B0A9AD9491C3Q28606742-2B88E323-63EC-4E21-BD4B-D7BBC0CEBB18Q28740383-758BB1D7-0434-4D4D-97B3-36C24459104BQ33835241-43D01C3C-9239-43AF-AF74-81DA2967DCC1Q33874162-A1001765-82FF-461D-9AFB-ED7EA633D19AQ34325957-0D88446D-46DD-4B20-8FD9-62D34E2FE80EQ35156542-13440A37-59F1-40D5-BA8F-D1AACD74C2FFQ36039385-AD15FB21-B935-4E4C-9A73-A2D7A8CCFAFBQ36154690-463F9865-F1A6-4395-9353-294735ACCFE1Q36205576-5AF8841B-6DAC-4E76-BC8A-C62221A2AECDQ36205629-6DEDA9EA-B7E9-4C91-8743-A49EA4E15FDCQ36259625-5DA08103-E19D-4F26-B13A-4ACDAA19047CQ36911457-B854F7D4-1F47-4843-A32C-FFA44AD6B792Q38030918-521ABF6B-13F9-426B-B623-8BC0344AE88AQ38126825-D7130424-47A1-4367-8E06-C1DF2EA0BFDEQ38156495-79E9779F-FCD8-45A2-8B57-F3D1541DF5C3Q38156497-D33D86C3-926F-4EC0-BF43-0F9A22EFB36AQ40089619-81C07E5C-02B1-4C53-BCA6-98083D531EB7Q40262562-EC5913A5-79FF-46CF-BEA1-2A356F007E84Q41907778-5096ADBB-6D30-4BF7-9AC6-B996F40B56ABQ42269762-DC3A6589-8AD3-4285-B438-A3D0596F23FAQ42726711-6C2737C1-3A6B-4CBB-BF10-659012746CA9Q46265783-ED8B7E1A-70D3-4F1F-AF03-03A3B5D84520Q46854258-A94ADFED-F126-422F-A504-337B35EBDEDDQ47160412-58F13E58-D49A-4C5F-A6E9-33D7396AA46FQ47644472-BB09BE09-4711-4760-BB4D-655D7022EA30Q51211568-90E5503D-2B54-47BD-A141-3E9AFD5571D4Q51277566-490770D8-C120-4D37-AC16-59C65B861506Q56933186-D749940C-7D24-4102-8684-72B797D6F6C0Q56933226-9DCA24F2-1370-4957-9326-D4C2916D8BB9Q56933333-45DADE16-130B-42A7-A888-F4CE71C3B3B6Q58707232-3BAD7304-5B41-442F-80C5-14FDFE5D739CQ59136344-44E23120-575F-47E8-A01C-64EF586224E0
P2860
Bacillus Calmette-Guérin vaccination reduces the severity and progression of tuberculosis in badgers.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Bacillus Calmette-Guérin vacci ...... on of tuberculosis in badgers.
@en
Bacillus Calmette-Guérin vacci ...... on of tuberculosis in badgers.
@nl
type
label
Bacillus Calmette-Guérin vacci ...... on of tuberculosis in badgers.
@en
Bacillus Calmette-Guérin vacci ...... on of tuberculosis in badgers.
@nl
prefLabel
Bacillus Calmette-Guérin vacci ...... on of tuberculosis in badgers.
@en
Bacillus Calmette-Guérin vacci ...... on of tuberculosis in badgers.
@nl
P2093
P2860
P50
P356
P1476
Bacillus Calmette-Guérin vacci ...... on of tuberculosis in badgers.
@en
P2093
Alexandra Tomlinson
Alistair Murray
Chris Cheeseman
Chris Hanks
Deanna Dalley
Fiona Rogers
Gavin J Wilson
George Gettinby
Jacky Brewer
Kate Palphramand
P2860
P304
P356
10.1098/RSPB.2010.1953
P577
2010-12-01T00:00:00Z